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Abstract 
Little is known whether genetic variants identified in genome-wide association studies interact to increase 
bladder cancer risk. Recently, we identified two- and three-variant combinations associated with a 
particular increase of bladder cancer risk in a urinary bladder cancer case-control series (IfADo, 1501 
cases, 1565 controls). In an independent case-control series (Nijmegen Bladder Cancer Study, NBCS, 
1468 cases, 1720 controls) we confirmed these two- and three-variant combinations. Pooled analysis of 
the two studies as discovery group (IfADo-NBCS) resulted in sufficient statistical power to test up to four-
variant combinations by a logistic regression approach. The New England and Spanish Bladder Cancer 
Studies (2080 cases and 2167 controls) were used as a replication series. Twelve previously identified 
risk variants were considered.  
The strongest four-variant combination was obtained in never smokers. The combination of 
rs1014971[AA] near APOBEC3A and CBX6, SLC14A1 exon SNP rs1058396[AG,GG], UGT1A intron SNP 
rs11892031[AA], and rs8102137[CC,CT] near CCNE resulted in an unadjusted odds ratio of 2.59 (95% CI 
= 1.93-3.47; P = 1.87×10
-10
), while the individual variant odds ratios ranged only between 1.11-1.30. The 
combination replicated in the New England and Spanish bladder Cancer Studies (ORunadjusted=1.60, 95% 
CI = 1.10-2.33; P = 0.013). The four-variant combination is relatively frequent, with 25% in never smoking 
cases and 11% in never smoking controls (total study group: 19% cases, 14% controls). In conclusion, we 
show that four high risk variants can statistically interact to confer increased bladder cancer risk 
particularly in never smokers. 
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Summary 
We identified and replicated specific combinations of three and four genetic variants that enhance bladder 
cancer risk in 5049 cases and 5452 controls. Different combinations were relevant in never, former and 
current smokers. The highest OR was obtained in never smokers (OR=2.59). 
 
Introduction 
Twin studies have suggested that approximately 30% of urinary bladder carcinomas (UBC) can be 
attributed to genetic predisposition [1]. Recently, genome-wide association studies have identified genetic 
variants at fifteen locations associated with UBC risk [2]. However, the identified variants show very small 
odds ratios (ORs) ranging between 1.11–1.24 [3]. An exception is the homozygous deletion variant of 
glutathione S-transferase M1 (GSTM1) with an OR ranging between 1.28 and 1.70 in large studies with a 
mean OR of about 1.43 in Caucasians [4–8]. 
    Relatively little is known whether the identified genetic variants interact to modulate UBC risk [9]. An 
open question is to which extent the common occurrence of several risk variants in an individual enhances 
risk. Recently, two large studies used a weighted allele score (or polygenic risk score) for each individual 
to model the consequences of common occurrence of risk alleles [10,11]. In the approach of these two 
studies each analysed variant was assigned a score from zero to two risk alleles, which were summed to 
an overall weighted score for each individual. Weights were based on the estimated OR of each variant. 
Subsequently, ORs of the score quartiles were estimated. Analysis of twelve variants in the study group of 
García-Closas et al. by this technique resulted in an OR of 2.94 for the highest scores (>75% quantile) 
compared to the lowest (<25% quantile) [11]. Similarly, analysis of seven SNPs in a Chinese study group 
resulted in an OR of 2.58 (>75% vs. <25% quantile) [10]. A limitation of this weighted allele score 
approach is that it does not identify the specific genetic variants that in combination enhance UBC risk as 
it does not model particular interactions of SNPs. Therefore, in 2012 our group applied a logistic 
regression approach in which all possible combinations of seven high risk variants were considered 
[12,13]. This approach identified specific three-variant combinations, where carriers of three high risk 
alleles had higher ORs than carriers of only one of the alleles [12]. 
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    A limitation of this study in the IfADo case-control series in 2012 was that an independent study group 
for replication was not available. Also, higher order than three-variant combinations could not be studied, 
because the case numbers in individual risk combination subgroups became smaller than 100, which did 
not allow analysis with sufficient statistical power. Meanwhile, the Nijmegen Bladder Cancer Study 
(NBCS), an independent ongoing case-control series comprising 1468 cases and 1720 controls (in the 
present analysis), has become available for this purpose [14–18]. In the present study we used this 
independent group to replicate the three-variant combinations previously identified in the total IfADo case-
control series. In addition, the IfADo and Nijmegen Bladder Cancer studies were combined to achieve 
sufficiently high case numbers to identify four-variant combinations. These four way combinations were 
further explored in the New England and Spanish Bladder Cancer Studies [6, 19–21].  
 
Materials and methods 
We used 2969 cases and 3285 controls from two case-control series in Germany (the multicentric IfADo 
case-control series, 1501 cases / 1565 controls) and the Netherlands (Nijmegen Bladder Cancer Study 
NBCS, 1468 cases / 1720 controls) with complete genotype data for the twelve investigated genetic 
variants as a discovery group and 2080 cases and 2167 controls from the New England and Spanish 
Bladder Cancer Studies with complete genotype data as a replication series (Table 1, Supplementary 
Table 1).  
 
IfADo case-control series 
In total 1501 confirmed UBC cases and 1565 controls without malignant disease of European descent of 
four case-control series from Germany and Hungary were collected by the Leibniz Research Centre for 
Working Environment and Human Factors at TU Dortmund (IfADo). All participants provided their written 
informed consent. Details are given in the Supplementary Materials and Methods and elsewhere [22].  
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    Genotypes of rs11892031[A/C], rs1495741[A/G], rs1058396[A/G], rs17674580[C/T], rs2294008[C/T], 
rs2978974[A/G], rs1014971[A/G], rs710521[A/G], rs798766[C/T], rs8102137[C/T], and rs9642880[G/T] 
were detected via TaqMan
®
 Assay [23]. The homozygous GSTM1 deletion was detected by the 
amplification of the GSTM1 DNA sequence segment with 218 base pairs by means of PCR [24–26]. 
Details are given in the Supplementary Materials and Methods. 
 
Nijmegen Bladder Cancer Study  
In the current study we used data of 1468 cases with primary UBC from the Nijmegen Bladder Cancer 
Study (NBCS) and 1720 controls from the Nijmegen Biomedical Study (NBS). The combined NBS-NBCS 
served as the Dutch discovery population in previous UBC genome-wide association studies [14–18].  
    Genotypes of rs11892031[A/C], rs1495741[A/G], rs1058396[A/G], rs2294008[C/T], rs2978974[A/G], 
rs1014971[A/G], rs710521[A/G], rs798766[C/T], rs8102137[C/T], and rs9642880[G/T] were determined 
using the Illumina HumanCNV370 BeadChip as described elsewhere [14]. Genotypes of rs17674580[C/T] 
were imputed using the IMPUTE v2.1 software as described elsewhere [14]. GSTM1 copy number 
variation (CNV) status was determined by an Applied Biosystems TaqMan Copy Number assay (Assay ID: 
Hs02575461_cn).  
 
New England and Spanish Bladder Cancer Studies 
This published case-control series includes 2080 cases and 2167 controls as described previously [6, 19-
21]. Information on ten genotypes determined in the IfADo and Nijmegen (NBCS) Bladder Cancer Studies 
were also available from the New England and Spanish Bladder Cancer Studies. In case of the SLC14A1 
SNPs rs1058396 and rs17674580 the SNPs rs10775480 and rs10853535 were used as proxies (r²=0.75 
and r²=0.66; data from 1000 Genomes Project, CEU (phase 3), ensemble genome browser version 87). A 
summary of study group characteristics is given in Table 1. 
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Statistical analysis  
Analyses were performed in the discovery group (total study group: IfADo and NBCS combined) and 
stratified for subgroups defined by smoking habits: never (less than 100 cigarettes/lifetime), former 
(stopped smoking before first diagnosis of UBC/recruitment), current (still smoking at UBC 
diagnosis/recruitment or just stopped smoking, for details, see Supplementary Materials and Methods) 
and ever smokers (former and current smokers combined). Unadjusted analyses were performed using 
asymptotic chi-squared tests, ORs, and 95% confidence intervals (95% CIs). Logistic regression and the 
Wald test adjusted for age, gender, smoking habits (if applicable), and study site (if applicable) was used 
for adjusted analyses. Unadjusted and adjusted effects of single variants on UBC risk were analysed in 
the complete study group, in the subgroups defined by smoking habits and separately in the IfADo and in 
the Nijmegen study group. SNPs were analysed assuming  recessive, dominant and additive mode of 
inheritance of the minor allele.  
    We used the NBCS to replicate the results of a previous study in the IfADo case-control series on seven 
variants (GSTM1, rs11892031[A/C], rs710521[A/G], rs1495741[A/G], rs9642880[G/T], rs8102137[C/T], 
rs1014971[A/G]) [12]. The frequency of the combinations in NBCS, unadjusted P values, ORs and 95% 
CIs were estimated for the ten best two- and three-variant combinations found in the total IfADo study 
group and in the subgroups defined by smoking habits. To avoid spurious findings we considered results 
as relevant if combinations were present in at least 100 cases and 100 controls from NBCS.  
    To investigate relevant combinations of twelve variants in the combined IfADo and Nijmegen study 
group we generated four binary variables for each of the eleven SNPs as described previously [12]. These 
variables coded either for a dominant or a recessive mode of inheritance of the minor allele or the 
respective complements which are necessary to define all combinations of dominant and recessive 
genotypes. So, we defined for a SNP with major [A] and minor [B] alleles the risk and reference 
genotypes:  
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(i) Dominant [B]: AB and BB (risk) vs. AA (reference), 
(ii) complement of dominant [B]: AA (risk) vs. AB and BB (reference), 
(iii) recessive [B]: BB (risk) vs. AA and AB (reference), 
(iv) complement of recessive [B]: AA and AB (risk) vs. BB (reference). 
    Two binary variables encoded either the GSTM1 null or the GSTM1 present genotype as risk factor. We 
used these 46 binary variables to define variant combinations. The genotype at risk of a combination was 
defined as presence vs. absence (reference) of a particular variant combination. P values (unadjusted) of 
the asymptotic chi-squared tests were computed for all two-, three- and four-variant combinations and 
used as an ordering criterion. The ten lowest nominal P values identified the ten best one- to four-variant 
combinations in the total study group and in the smoking habits subgroups. The analyses were restricted 
to combinations with a minimum frequency of 100 cases and 100 controls in the risk and in the reference 
group.  
    Two separate analyses were performed for the total study group as well as for the smoking habits 
subgroups: Analysis I comprised a detailed analysis of the best one- to four-variant combinations. 
Analysis II of the ten best combinations was used to confirm the results of Analysis I using a set of 
combinations with similarly low P values. 
Analysis I. For the best (lowest unadjusted P value) individual variants and two-, three- and four-variant 
combinations unadjusted and adjusted P values, ORs and 95% CIs were estimated in the discovery group 
(IfADo and NBCS combined) as well as in the independent case-control series of the New England and 
Spanish Bladder Cancer Studies. 
The stability of the ORs of the best combinations was investigated by bootstrap sampling in the discovery 
group as described previously [12]. Likelihood ratio (LR) tests were used to check if the effect of the 
variant combinations was due to multiplicative interaction or due to main effects of the single variants in 
the combination. To test if the unadjusted ORs of the k-variant combinations increase significantly with 
increasing number k of combined variants, LR tests were used adding successively the best single 
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variant, the best two-, three- and four-variant combinations to a logistic regression model. Similarly, we 
used LR tests to check whether this increase in ORs could be achieved alone by adding the single 
variants, which were present in the best combinations, as main effects. Finally, we checked the relevance 
of addition of a main effect and an interaction term (multiplicative) in one step by LR tests.  
Analysis II. The ten best two-, three- and four-variant combinations were used to compare subgroup 
(never vs. former and current, never vs. ever smokers) differences regarding the frequency of the single 
variants in the k-variant combinations. Exact chi-squared tests were used to compare never, former and 
current smokers and Fisher's exact tests for pairwise comparisons. Increase of the ORs with increasing 
number k of combined variants was tested using the Tukey test.  
    All calculations were performed using the software R, version 3.0.1 (R Development Core Team, 2014) 
and SAS/STAT, versions 9.3 and 9.4 (SAS Institute Inc., Cary, NC). Details of the statistical analysis are 
given in the Supplementary Materials and Methods.  
 
 
Results 
Replication of previously reported two- and three-variant combinations in the NBCS 
In a previous study we reported ORs of seven genetic variants individually, as well as of two- and three-
variant combinations in the IfADo study group [12,13]. In a first step of the present study we performed 
similar analyses in the NBCS and estimated the individual and combination effects. Unadjusted ORs of 
the individual variants with respect to UBC risk were similar between both study groups (Supplementary 
Tables 1B, 2). In both study groups, IfADo and NBCS, the lowest P values were obtained for the GSTM1 
deletion variant and for rs9642880[TT]. Moreover, the previously reported strongest two- and three-variant 
combinations identified in the IfADo study group [12,13] resulted in similar unadjusted ORs in the NBCS 
(Table 3). The top ten two-variant combinations identified in the IfADo study group were all significant also 
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in the NBCS and the ORs obtained from both independent groups never differed by more than 0.14 (Table 
3). Also the top ten three-variant combinations identified in the IfADo study group were all significant in the 
NBCS (Table 3). The analyses of the individual variants as well as two- and three-variant combinations 
were repeated in the subgroups of ever, current, former and never smokers (Supplementary Tables 3, 4). 
Unadjusted ORs of the individual variants were also quite similar between both study groups stratifying for 
smoking habits (Supplementary Table 3). In current and never smokers case numbers were too low 
(N<100 per risk group in cases and in controls) to allow a comparison of the NBCS and the IfADo study 
groups (Supplementary Table 4). However, in ever and former smokers when case and control numbers 
exceeded N=100 similar ORs were obtained in both study groups (Supplementary Table 4). Age and sex 
distributions were similar between both study groups, while the NBCS contained less never smokers 
compared to the IfADo case-control series (Table 1). In conclusion, both study groups were similar with 
respect to the influence of the individual variants as well as previously identified two- and three-variant 
combinations. Therefore, a combination of the two study groups with the aim to identify possible four-
variant combinations seemed justified.  
 
Interplay of high-risk genetic variants in the combined IfADo-Nijmegen case-control series: 
relevance of four-variant combinations  
To study possible interactions between genetic variants in a larger case-control series as previously 
possible [12], the aforementioned NBCS and IfADo study groups were combined resulting in a series of 
2969 UBC cases and 3285 controls (Table 1). Data of twelve genetic variants were available in both study 
groups (Supplementary Table 1B). Five additional variants were analysed compared to the previous study 
[12]. All analysed variants have been reported to be individually associated with UBC risk. In the present 
study all but rs2978974 of the individually analysed variants were significantly associated in the 
unadjusted analysis (additive genetic model, Supplementary Table 1B). After adjustment for age, gender 
and smoking habits ten of them remained significant while rs2978974 (ORadditive=1.01) and rs149571 
(ORadditive=1.08) were not significant assuming an additive, recessive or dominant mode of inheritance 
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(Supplementary Tables 1B, 2). The significant SNPs all showed ORs between 1.09 and 1.27 (additive 
model; significant recessive: 1.30-1.38; significant dominant 1.13-1.35; Supplementary Table 2). 
    All possible two-, three- and four-variant combinations were tested, amounting to a total of 118 888 
analysed effects. The resulting best combinations (Analysis I) showed a continuous increase in 
unadjusted ORs for increasing variant numbers between one and four (Figure 1A, B; Table 3). A 
remarkable difference was obtained for smokers and never smokers. Variant combinations resulted in 
higher ORs for the never smokers. Ever smokers showed the lowest ORs, while former and current 
smokers ranged in between (Figure 1A, B). The total group (Table 3) showed similar results as the ever 
smokers, which can be explained by the fact that most of the cases (70%) were current or former 
smokers. Higher than four-variant combinations were not tested, because of small case numbers and thus 
statistical power limitations. For up to four-variant combinations the case numbers in all subgroups were 
higher than N=100 (Supplementary Table 8).  
    Next, we tested if an increase of the number of combined variants resulted in significantly 
increased/decreased risk (Figure 2A, Supplementary Table 6A). The best one- to four-variant 
combinations were added successively to the model, to test if the resulting increases in the likelihood ratio 
statistics are significant. For never smokers significant increases in unadjusted ORs were obtained for all 
one to four variant combinations added in a stepwise manner. The strongest individual variant for never 
smokers, rs1014971[AG,GG], was significant in a univariate logistic regression model with a likelihood 
ratio statistic of LR=13.16, P=0.0003 (Figures 1C, 2A; Supplementary Table 6A). Addition of the best two-
variant combination (rs1014971, rs17674580) to the logistic regression model with the best variant 
(rs1014971) alone increased the likelihood ratio statistic significantly by LR=9.92, P=0.0016. Adding the 
best three-variant combination (rs1014971, rs1058396, rs11892031) to the model with the main 
(individual) effect and the two-variant combination further improved the likelihood ratio statistic by 
LR=9.75, P=0.0018. Further inclusion of the best four-variant combination (rs1014971, rs1058396, 
rs11892031, rs8102137), which now has to compete with the best individual, two- and three-variant 
combinations led to additionally improved significance (LR=12.01, P=0.0005). Similar constellations were 
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obtained for the former smokers and for the total group (Figure 2A). For the ever and for the current 
smokers significant improvements for the likelihood ratio statistics were obtained for up to three-variant 
combinations but not for a further added four-variant combination.  
    To analyse whether the improvement of the model fit was due to addition of further individual variants 
present in the combinations or rather than interaction effects we repeated the analysis adding 
successively the new individual variants in the two- to four-variant combinations as main effects in the 
logistic regression model (Supplementary Figure 1A, Supplementary Table 6B). Furthermore, we added 
both – interactions and corresponding individual variants – in each step to the model (Supplementary 
Figure 1B, Supplementary Table 6C). For the improvement of the model fit the interactions were more 
relevant than the corresponding main effects. Additionally, we tested the significance of each two-, three- 
and four-way interaction in presence of the corresponding individual variants as main effects separately 
for each top combination (Supplementary Table 7). Remarkably, the four-way interactions were still 
significant in a logistic regression model that also contained the corresponding main effects. For instance, 
in never smokers the interaction term rs1014971[AA] × rs1058396[AG,GG] × rs11892031[AA] × 
rs8102137[CC,CT] (P=0.0003) was significant in a common model containing also rs1014971[AA] 
(P=0.4318), rs1058396[AG,GG] (P=0.1236), rs11892031[AA] (P=0.1207) and rs8102137[CC,CT] 
(P=0.8005) which were not significant in presence of the interaction term (Supplementary Table 7).  
    The analyses of Figures 1 and 2A focussed on a single top performing combination. To study if the 
described patterns remain stable for further relevant combinations we included the ten best combinations 
for one to four variants (Analysis II) into a box plot analysis (Figure 2B, Supplementary Table 8). A similar 
pattern was obtained for the ten top combinations (Figure 2B) compared to the best one (Figure 1). The 
"top ten approach" additionally offered the advantage that the assumed increase/decrease in the 
unadjusted ORs by increase of the number of combined variants could be analysed by pairwise 
comparisons. This illustrated that the increase in mean ORs from individual effects to four-variant 
combinations was significant for never, former and current smokers (Figure 2B). For the total group and 
ever smokers mean ORs increased significantly combining up to three-variants.  
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Different SNP combinations are relevant in ever and never smokers 
As demonstrated in the previous paragraph genetic variants interact with respect to UBC risk. Next, we 
analysed if the same or different variants were relevant in ever and never smokers. The variant with the 
lowest (unadjusted) P value in ever smokers was the GSTM1 deletion (Table 3). For two-variant 
combinations SNP rs9642880 near MYC together with GSTM1 deletion resulted in the lowest P value. 
Next, the 5' UTR PSCA SNP rs2294008 and the TACC3 intron SNP rs798766 amended the most 
significant combinations in ever smokers.  
    A completely different sequence of best variant combinations was obtained for the never smokers 
(Table 3). The most significant individual variant was rs1014971 near APOBEC3A. Next rs1014971 was 
amended by the SLC14A1 intron SNP rs17674580 to form the strongest two-variant combination. The 
three-variant combination included again rs1014971 together with the second SLC14A1 SNP (rs1058396 
instead of rs17674580 as in the two-variant combination) and the UGT1A intron SNP rs11892031. The 
four-variant combination with the lowest P value additionally included rs8102137 near CCNE1. In 
conclusion, considering the most significant combinations up to four variants there was no overlap 
between ever and never smokers (Table 3).  
    Next, we further analysed the group of ever smokers (2069 cases, 2136 controls) which consisted of 
former (1393 cases, 1477 controls) and current (676 cases, 659 controls) smokers (Supplementary Figure 
2). For both, ever and current smokers, the deletion of phase II detoxifying GSTM1 was identified as the 
most significant variant (Table 3). In contrast, GSTM1 was not among the best four-variant combinations 
in former smokers. Instead former and ever smokers overlapped in rs9642880 near the MYC oncogene. 
This suggests that quitting cigarette smoking may lead to a shift in relevance for the population at risk from 
detoxifying GSTM1 to MYC, a gene which is known to act as a proto-oncogene. To identify the most 
characteristic differences between ever smokers (considering also former and current smokers) and never 
smokers we analysed the top ten combinations of two, three and four variants in these subgroups (Table 
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4, Supplementary Tables 8, 9). The frequency of the specific variant among the top ten combinations was 
analysed and significant differences between the four groups analysed by a chi-squared test. This led to 
the observations that (i) GSTM1 null was significantly more frequent in ever and current smokers than in 
never smokers and more frequent in current compared to former smokers, supporting the observations in 
Table 3 and Figure 1C that GSTM1 lost its relevance when smoking had been ceased. So, GSTM1 is a 
typical "current smoker variant". (ii) Rs1014971 near APOBEC3A was more frequent in never smokers, 
compared to ever, current and former smokers indicating that this variant is a typical "never smoker SNP". 
(iii) Rs9642880 near MYC was more frequent in ever and former smokers compared to never smokers 
and more frequent in former compared to current smokers. Therefore, rs9642880 is a typical "former 
smoker SNP" and seems to be relevant for cigarette smoke exposed individuals only if smoking occurred 
in the past with no current exposure.  
 
Replication of the four-variant combinations in independent case-control series 
Finally we tested, whether the four-variant combinations, particularly the combination rs1014971[AA] × 
rs1058396[AG,GG] × rs11892031[AA] × rs8102137[CC,CT] in never smokers, identified in the combined 
IfADo-NBCS case-control series, could be confirmed in independent study groups. For this purpose, 
corresponding SNP data from 2080 additional bladder cancer cases and 2167 controls (Table 1) were 
available from the published New England and Spanish Bladder Cancer Studies [6, 19–21]. The 
rs1014971[AA] × rs1058396[AG,GG] × rs11892031[AA] × rs8102137[CC,CT] combination in never 
smokers was confirmed in the New England and Spanish Bladder Cancer Studies resulting in increasing 
(unadjusted) ORs of 1.32 for the single variant to 1.60 for the four-variant combinations, respectively 
(Table 3B). Similarly, the four-variant combination in current smokers (GSTM1 null × rs11892031[AA] 
×rs1058396[AG,GG] × rs1014971[AA,AG]) was confirmed (Table 3B). In contrast, the four-variant 
combination in former smokers (rs9642880[TT] × rs8102137[CC,CT] × rs1495741[AA,AG] × 
rs17674580[CC,CT]) could not be replicated, possibly due to the fact that former smokers are much more 
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heterogeneous compared to never or current smokers. The adjusted logistic regression (Supplementary 
Table 5C) led to similar results as the unadjusted analysis shown in Table 3B.  
 
Discussion 
An important question is whether genetic variants can interact leading to higher ORs for combined high 
risk alleles than the combination of individual variants alone. In a previous study we identified three-variant 
combinations of seven confirmed UBC risk variants in the IfADo case-control series and obtained 
remarkable differences between ever and never smokers [12,13]. In the present study we used the NBCS 
to confirm the previous results. Importantly, all frequent three-variant combinations could be replicated. In 
particular, we confirmed the results for the total study group and the s bgroups of ever and former 
smokers. Three-variant combinations identified in current and never smokers were not significant, possibly 
because of their low frequency (N<100 in cases and in controls).  
    As results and study group characteristics in were comparable we combined both case-control series to 
analyse up to four-variant combinations with sufficient power. Moreover, five further UBC risk variants 
were added to the combination analysis. We restricted the analysis to combinations present in at least 100 
cases and controls to obtain robust results. We also restricted the analysis to four-variant combinations to 
avoid a bias towards frequent variants in higher-fold combinations.  
    The strongest four-variant combination in never smokers was obtained for the high risk alleles of 
rs1014971[AA] near APOBEC3A and CBX6, the SLC14A1 exon SNP rs1058396[AG,GG], the UGT1A 
intron SNP rs11892031[AA], and rs8102137[CT,CC] near CCNE1. The combination resulted in an 
unadjusted OR of 2.59 (95% CI=1.93-3.47, P=1.87×10
-10
; Table 3). This four-variant combination was still 
relatively frequent, with percentages of 25% and 11% in cases and controls, respectively. The relatively 
high OR of the combination (OR=2.59) is remarkable considering that the individual ORs were small 
(OR=1.11-1.30; Supplementary Tables 3K, L). Furthermore, the individual variants were not significant 
(P ≥ 0.1207) in a common logistic regression model in presence of the four-way interaction effect 
Ac
ce
pte
d M
an
us
cri
pt
15 
 
 
 
(P=0.0003; Supplementary Table 7). LR tests also showed that the increase from two- to four-variant 
combinations led to a significant increase in ORs for each step. Next, we tested, whether the four-variant 
combination in never smokers (rs1014971[AA] × rs1058396[AG,GG] × rs11892031[AA] × 
rs8102137[CC,CT]), identified in the combined IfADo-NBCS study group, could be confirmed in an 
independent case-control series, the published New England and Spanish Bladder Cancer Studies [6, 19–
21]. The increased risk replicated in this group (ORunadjusted=1.60, 95% CI=1.10-2.33, P=0.0130) with 
similar frequencies of the combination (18% in cases, 12% in controls, Table 3B).  
    The main effect in never smokers, i.e. the most important individual variant, of the four-variant 
combination was attributable to rs1014971[AA]. This SNP maps to an intergenic region close to the 
chromobox homolog 6 (CBX6) and apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3A 
(APOBEC3A) genes [6]. CBX genes have been reported to be involved in regulation of heterochromatin 
while APOBEC3A seems to be associated with genetic instability [27–29]. The second SNP in the four-
variant combination rs1058396[AG,GG] is a solute carrier family 14 (urea transporter), member 1 (Kidd 
blood group) (SLC14A1) exon SNP [15]. SLC14A1 is a urea transporter in the bladder which influences 
urine concentration as measured by specific gravity [30]. The third variant of the four-variant combination 
was rs11892031[AA], an intron SNP of the phase II metabolism gene UDP glucuronosyltransferase 1 
family, polypeptide A complex locus (UGT1A) involved in glucuronidation [6,31,32]. Variant number four in 
the combination was rs8102137[CC,CT] near cycline E1 (CCNE1) [6]. CCNE1 is involved in cell cycle 
transition from G1 to S phase [6]. In conclusion, the four strongest interacting SNPs for never smokers 
seem to be associated with the biological processes of chromatin modification, genetic stability, 
detoxification and proliferation. This leads to the question why there is an interaction effect between these 
variants. We speculate that the interacting variants seem to belong to completely different biological 
processes, which may be assigned to detoxification, proliferation and DNA stability, thereby covering a 
broad set of functions relevant for carcinogenesis, instead of focusing on a specific single function. 
However, this interpretation should be treated with caution, since little is known about the functions of the 
variants themselves, let alone the combinations. 
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    Increased ORs for the strongest four-variant combinations in the combined IfADo-Nijmegen study group 
were obtained in the never as well as the current smokers (Table 3A). The results of both four-variant 
combinations were confirmed in the New England and Spanish Bladder Cancer Studies, although ORs 
were numerically lower (but P values still significant; Table 3B), which is not unusual for analysis of an 
independent replication series. The strongest interaction of the entire study, the four-variant combination 
in never smokers, is characterized by a monotonous trend, where each added variant leads to increased 
ORs. However, also other scenarios were obtained. The four-variant combinations in current and former 
smokers show a non-monotonous trend with a decreased OR by the two-variant combination but 
increased ORs associated with the following variants (Table 3A). Such combinations are possible, 
because the here applied approach searches for the strongest variant combination independently within 
all two-, three- and four-variant combinations – ignoring that a best lower fold combination has been found 
already. Remarkably, the previous set of combined variants usually kept stable with increasing numbers of 
combined variants. So, the switch from a protective two-variant combination to a risk combination of three 
and four variants is easily explained: Either low risk genotypes were added to the low risk genotype of the 
most important variant in the subgroup (GSTM1 positive for current smokers, rs9642880[GG,GT] for 
former smokers) or vice versa high risk genotypes were combined (Table 3A). Importantly, the four-variant 
combinations as well as the non-monotonous trend were confirmed in the New England and Spanish 
Bladder Cancer Studies (Table 3B).  
    The variants of the best four-variant combination of the subgroup of ever smokers showed no overlap 
with that of the never smokers. In smokers the strongest variant of the four-variant combination was the 
GSTM1 deletion. GSTM1 is known to be involved in detoxification of cigarette smoke carcinogens [8,33–
35]. Already in previous publications the relevance of this polymorphism has been demonstrated 
particularly in smokers and individuals occupationally exposed to polycyclic aromatic hydrocarbons 
(PAHs) [8,11,36]. Interestingly, after cessation of occupational and/or environmental exposure to PAHs 
the GSTM1 polymorphism was no longer relevant [37]. The previous interaction analysis of the IfADo 
case-control series comprising seven of the investigated polymorphisms also identified the GSTM1 
deletion as the most important variant in smokers [12]. The second variant in the four-variant ever smoker 
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combination was rs9642880, a variant approximately 30 000 bases upstream of MYC which has been 
reported to be associated with RNA levels of the oncogene [16,31,38]. The biological function of the third 
and the fourth variant in the combination, the glycoprotein PSCA and the microtubule regulating TACC3 
variants rs2294008 and rs798766 in relation to bladder carcinogenesis is still not fully understood 
[17,31,39–43]. Interactions of the GSTM1 deletion, rs9642880 and rs2294008 but not rs798766 with 
smoking habits have also been found in a large UBC study (3942 cases, 5680 controls) [11]. Missense 
SNP rs2294008 alters the PSCA start codon and results in less promoter activity but more mRNA [39,40]. 
PSCA owning an androgen responsive element (ARE) in its promoter region influences PSCA expression 
[44]. It is hypothesized that gender-specific UBC risk might be modulated via ARE-depending PSCA 
transcription activity in presence of rs2294008. However, relevant signalling pathways remain unclear [41]. 
The functional role of the transforming, acidic coiled-coil containing protein 3 (TACC3) intron SNP 
rs798766 is still unclear [17,31]. TACC3 is a centrosomal adaptor protein that is involved in spindle 
microtubule dynamics during cell division [42,43]. In particular, TACC3 protein complexes seem to be 
essential for mitotic spindle assembly and dynamics and, hence, for prevention of genomic instability 
[42,43]. However, the observed association of rs798766 with UBC risk might also be due to the nearby 
FGFR3 gene. Fibroblast growth factor receptors play a key role in activation of signalling pathways, for 
instance, the RAS/MAPK, PLCγ1, PI3K, and STAT pathways that regulate proliferation, migration, and 
differentiation [45]. Point mutations in the fibroblast growth factor receptor 3 (FGFR3) gene and increased 
expression of the variant gene are common in low-grade non-invasive papillary urothelial bladder 
carcinomas [45–47]. Overexpression of wild-type FRGR3 is more common in invasive than in non-
invasive tumors [45,47]. Recently, FGFR3-TACC3 gene fusions have been detected in UBC as well as 
glioblastoma patients and cell lines [46–48]. The fusion seems to result in a loss of the C-terminus of 
FGFR3 and an overexpression of the FGFR3-TACC3 fusion product [47,48]. The protein seems to be 
highly oncogenic in vivo and in vitro and can be assumed to induce signalling via the MAPK pathway in 
urothelial cells [47,48].  
    It should be considered that differences in variant combinations were not only observed between ever 
and never smokers, but also between current and former smokers. The subgroup of former smokers lost 
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the "smoker variant" GSTM1 in their best four-variant combination. Instead, the "never smoker SNP" 
rs8102137 5.8 kb upstream cyclin E1 (CCNE1) occurs in the best four-variant combination of former 
smokers. The SNP rs9642880 near MYC is the strongest variant in the subgroup of former smokers. It is 
not present in the best four-variant combination of current smokers, nor of never smokers. However, it 
should be taken into account that this four-variant combination identified in the combined IfADo-Nijmegen 
case-control series was not confirmed in the replication series and should therefore be discussed with 
caution. Reasons for the discrepant result may be the general heterogeneity of the subgroup of former 
smokers, differences in definition and determination of a status as a former smoker which is associated 
with a higher degree of uncertainty than in case of current or never smokers. Or this observation could be 
a chance finding.  
    In conclusion, the present logistic regression based approach demonstrated that specific combinations 
of three to four variants confer UBC risk. The highest unadjusted OR was obtained for a four-variant 
combination in the subgroup of never smokers (OR=2.59). Importantly, this four-variant combination was 
confirmed in an independent case-control series. Moreover, different SNP combinations were obtained for 
current smokers (OR=1.61) and former smokers (OR=2.13). The dominant SNP for never smokers is 
rs1014971 near APOBEC3A. The most important "smoker variant" is GSTM1, while former smokers shift 
to rs9642880 near MYC. The study demonstrates the strength of logistic regression approaches for SNP 
interactions that identify specific interaction profiles. This present study further supports the concept, 
according to which individual polymorphisms add only little to overall UBC risk, but the combined presence 
of many individually weak SNPs leads to substantially increased ORs [3]. 
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Abreviations 
APOBEC3A: apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3A; CBX6: 
chromobox homolog 6; CCNE1: cycline E1; CI: confidence interval; FGFR3: fibroblast growth 
factor receptor 3; GSTM1: glutathione S-transferase M1; IfADo: Leibniz Research Centre for 
Working Environment and Human Factors at TU Dortmund; IQR: interquartile range; LR: 
likelihood ratio; MAF: minor allele frequency; MYC: v-myc avian myelocytomatosis viral 
oncogene homolog; NA: not available; NAT2: N-acetyltransferase 2; NBCS: Nijmegen Bladder 
Cancer Study; NBS: Nijmegen Biomedical Study; OR: odds ratio; PI3K: phosphatidylinositol-4,5-
bisphosphate 3-kinase; PLCγ1: phospholipase C, gamma 1; PSCA: prostate stem cell antigen; 
SD: standard deviation; SLC14A1: solute carrier family 14 (urea transporter), member 1 (Kidd 
blood group); SNP: single nucleotide polymorphism; STAT: signal transducer and activator of 
transcription; TACC3: transforming, acidic coiled-coil containing protein 3; TP63: tumor protein 
p63; UBC urinary bladder cancer; UGT1A: UDP glucuronosyltransferase 1 family, polypeptide A 
complex locus  
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Table legends 
Table 1. Study group characteristics of the Discovery and Replication series. For detailed information on 
the analysed variants, see Supplementary Table 1. 
Table 2. The previously reported top ten two- and three-variant combinations in the IfADo study group 
[12,13] showed similar unadjusted ORs in the Nijmegen Bladder Cancer Study (NBCS). The comparison 
of the ten best two- and three-variant combinations in the subgroups of smokers (ever, current, former) 
and never smokers are given in Supplementary Table 4. P values P ≤ 0.05 are printed bold. 
Table 3. Different variant combinations are relevant in smokers and never smokers. The best (lowest P 
value, minimum frequency 100) single polymorphisms and the best two- to four-variant combinations 
discovered in the combined IfADo and Nijmegen Bladder Cancer Studies, unadjusted odds ratios (OR), 
95% confidence intervals (CIs) and P values are shown (A). Furthermore the unadjusted OR of the 
reference group (complement of the variant combination) compared to the variant combination is given 
(1/OR). Both, OR and 1/OR are highlighted grey and are printed bold in case of exceeding 1 significantly. 
The best combinations found in current and never smokers could be replicated in the New England and 
Spanish Bladder Cancer Studies (B) using rs10775480 and rs10853535 as proxies for rs1058396 and 
rs17674580 (r²=0.75 and r²=0.66) [19]. Results for the IfADo and Nijmegen study groups as well as age, 
gender, smoking habits and study group adjusted OR, 95% CIs and P values of the Wald test are given in 
Supplementary Table 5. Performance of the best combinations in the other subgroups is shown in 
Supplementary Table 10.  
 
A. Best combinations in the Discovery series (combined IfADo case-control series and Nijmegen 
Bladder Cancer Study) 
B. Replication series: New England and Spanish Bladder Cancer Studies 
 
Table 4. Variants in the ten best four-variant combinations differ between smokers and never smokers. 
Subgroups are compared regarding the occurrence of each variant in the ten best combinations by chi-
squared or Fisher's exact tests. Unadjusted P values, ORs and 95% CIs of all ten best single variants, 
two-, three and four-variant combinations are given in Supplementary Table 8A-E. Tests for the ten best 
two- and three-variant combinations are given in Supplementary Table 9A, B. P values P ≤ 0.05 are 
printed bold. 
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Figure legends 
Figure 1. The best combinations of up to four risk variants showed a continuous increase in unadjusted 
ORs and a different composition in smoker subgroups. Combinations of twelve variants were analysed in 
the combined IfADo and Nijmegen case-control series. Unadjusted ORs of the best single variants, two-, 
three-, and four-variant combinations in never and ever smokers (panel A) and in current and formers 
smokers (panel B, transparent lines indicate results of never and ever smokers as reference) are given. 
The height and width of the diamonds correspond to the square root of the combination frequency of 
controls and cases in the subgroup. Vertical bars indicate the 95% CIs. The overlap of polymorphisms in 
the top one to four-variant combinations in the subgroup analyses of ever, current and former smokers 
indicated that GSTM1 is more relevant for current smokers in contrast to rs9642880 (MYC) that seems to 
be more relevant in former smokers (panel C). Associated genes are given in parenthesis. 
Figure 2. The increase of unadjusted ORs of up to four-variant combinations was significant for the best 
and the ten best combinations.  
    A. Impact of best one to four-variant combinations on UBC risk in a common logistic regression model 
(without adjustment for further covariates) in the combined IfADo-Nijmegen study group ("All") and 
stratified by smoking habits ("Ever", "Current", "Former" and "Never" smokers). Likelihood ratio tests 
indicated that the best one to three (ever and current smokers) or four-variant combinations (all combined, 
former and never smokers) had a significant impact on UBC risk in a common logistic regression model. 
For the total study group as well as for all subgroups of ever (current and former smokers combined), 
current, former and never smokers the likelihood ratio (LR) statistic for addition of the respective best 
variant combination to a logistic regression model that contained all lower order best combinations was 
plotted successively, i.e. the LR statistic for the best main effect compared to the null model, the LR 
statistic for the model containing the main effect and the best two-variant combination compared to the 
model with the main effect only, etc. Significant combinations are indicated by * in case of P < 0.05 and by 
** in case of P < 0.001. The best combinations are given in Table 3, the LR statistics and corresponding P 
values are given in Supplementary Table 6A. 
    B. The ten best unadjusted ORs of single variants, two-, three- and four-variant combinations show a 
significant increase for increasing numbers of combined variants in smokers and never smokers. Box plots 
of the ten best unadjusted ORs (i.e. having the lowest unadjusted P value) of one to four-variant 
combinations with at least 100 cases and 100 controls in the combined study group ("All") or subgroup of 
ever, current, former and never smokers were plotted. Pairwise comparisons of the ORs of the ten best 
risk variants and two- to four-variant combinations were performed using the Tukey test. Significant 
increases were obtained for up to three-way (all combined, ever smokers) or four-way (current, former and 
never smokers) combinations, respectively. Significant variants and combinations are indicated by * in 
case of P < 0.05 and by ** in case of P < 0.001. The ten best one- to four variant combinations are given 
in Supplementary Table 8A-E.  
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Table 1. Study group characteristics of the Discovery and Replication series. For detailed information on the analysed variants, see Supplementary 
Table 1.  
  Discovery series  Replication series 
 IfADo  NBCS Combined 
New England and Spanish 
Bladder Cancer Studies 
  Cases (%) Controls (%) Cases (%) Controls (%) Cases (%) Controls (%) Cases (%) Controls (%) 
Gender   
      Female 305 (0.20) 570 (0.36) 265 (0.18) 864 (0.50) 570 (0.19) 1434 (0.44) 353 (0.17) 407 (0.19) 
Male 1196 (0.80) 995 (0.64) 1189 (0.81) 843 (0.49) 2385 (0.80) 1838 (0.56) 1727 (0.83) 1760 (0.81) 
Missing 0 (0.00) 0 (0.00) 14 (0.01) 13 (0.01) 14 (0.01) 13 (0.00) 0 (0.00) 0 (0.00) 
Total 1501 1565 1468 1720 2969 3285 2080 2167 
Smoking habits   
      Ever 1109 (0.74) 890 (0.57) 960 (0.65) 1246 (0.72) 2069 (0.70) 2136 (0.65) 1696 (0.82) 428 (0.20) 
  Current 404 (0.27) 297 (0.19) 272 (0.19) 362 (0.21) 676 (0.23) 659 (0.20) 776 (0.37) 428 (0.20) 
  Former 705 (0.47) 593 (0.38) 688 (0.47) 884 (0.51) 1393 (0.47) 1477 (0.45) 920 (0.44) 932 (0.43) 
Never 300 (0.20) 658 (0.42) 106 (0.07) 457 (0.27) 406 (0.14) 1115 (0.34) 305 (0.15) 688 (0.32) 
Missing 92 (0.06) 17 (0.01) 402 (0.27) 17 (0.01) 494 (0.17) 34 (0.01) 79 (0.04) 119 (0.06) 
Age   
      Min-Max 20-95 20-100 25-93 27-79 20-95 20-100 22-77 20-76 
Median (IQR) 68 (16) 67 (18) 64 (13) 63 (15) 66 (14) 65 (16) 67 (14) 66 (14) 
Mean (SD) 66.9 (11.29) 63.13 (15.49) 62.1 (9.97) 61.51 (10.33) 64.76 (10.99) 62.28 (13.08) 65.4 (10) 64.4 (10.3) 
20-55 years 246 (0.16) 386 (0.25) 289 (0.20) 476 (0.28) 535 (0.18) 862 (0.26) 369 (0.18) 434 (0.22) 
56-64 years 366 (0.24) 303 (0.19) 358 (0.24) 501 (0.29) 724 (0.24) 804 (0.24) 457 (0.22) 477 (0.22) 
65-71 years 355 (0.24) 402 (0.26) 363 (0.25) 453 (0.26) 718 (0.24) 855 (0.26) 580 (0.28) 643 (0.30) 
72+ years 529 (0.35) 473 (0.30) 189 (0.13) 277 (0.16) 718 (0.24) 750 (0.23) 674 (0.32) 613 (0.28) 
IQR: interquartile range (Q75%-Q25%), SD: standard deviation 
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Table 2. The previously reported top ten two- and three-variant combinations in the IfADo study group [12,13] showed similar unadjusted ORs in the 
Nijmegen Bladder Cancer Study (NBCS). The comparison of the ten best two- and three-variant combinations in the subgroups of smokers (ever, 
current, former) and never smokers are given in Supplementary Table 4. P values P ≤ 0.05 are printed bold. 
 Schwender et al. (2012)  NBCS  
  95% CI   95% CI  
Variant 
combination Reference 
Min. 
freq. 
OR 
diff. Variant combination OR Lower Upper P value OR Lower Upper P value Cases Controls Cases Controls 
Ten best two-variant combinations 
  rs11892031[AA] x GSTM1 null 1.42 1.23 1.64 9.50×10
-07
 1.29 1.12 1.49 0.0003 725 740 743 980 725 0.13 
  rs9642880[GG,GT] x GSTM1 present 0.70 0.60 0.81 1.57×10
-06
 0.69 0.60 0.80 1.30×10
-06
 443 660 1025 1060 443 0.00 
  rs710521[AA,AG] x GSTM1 null 1.41 1.23 1.63 1.67×10
-06
 1.32 1.15 1.52 8.67×10
-05
 804 822 664 898 664 0.09 
  rs8102137[CC,CT] x GSTM1 null 1.43 1.23 1.66 3.73×10
-06
 1.31 1.13 1.52 0.0005 500 487 968 1233 487 0.12 
  rs9642880[GT,TT] x GSTM1 null 1.39 1.21 1.61 5.41×10
-06
 1.34 1.16 1.55 4.66×10
-05
 662 653 806 1067 653 0.05 
  rs710521[AA,AG] x GSTM1 present 0.73 0.63 0.84 1.45×10
-05
 0.81 0.70 0.93 0.0031 580 769 888 951 580 -0.08 
  rs11892031[AA,AC] x GSTM1 null 1.36 1.19 1.57 1.46×10
-05
 1.30 1.13 1.49 0.0003 847 882 621 838 621 0.07 
  rs9642880[TT] x rs710521[AA,AG] 1.43 1.21 1.70 2.92×10
-05
 1.36 1.15 1.61 0.0003 374 345 1094 1375 345 0.07 
  rs710521[AA] x GSTM1 null 1.39 1.19 1.62 3.42×10
-05
 1.36 1.16 1.58 9.52×10
-05
 483 457 985 1263 457 0.03 
  rs11892031[AA,AC] x GSTM1 present 0.74 0.65 0.86 3.77×10
-05
 0.77 0.67 0.88 0.0002 616 835 852 885 616 -0.02 
Ten best three-variant combinations               
rs710521[AA,AG] x rs11892031[AA] x 
GSTM1 null 1.48 1.28 1.70 8.22×10
-08
 1.31 1.14 1.51 0.0002 687 691 781 1029 687 0.17 
rs9642880[GG,GT] x rs710521[AA,AG] x 
GSTM1 present 0.67 0.58 0.78 1.98×10
-07
 0.73 0.63 0.85 3.97×10
-05
 417 606 1051 1114 417 -0.06 
rs8102137[CC,CT] x rs11892031[AA] x 
GSTM1 null 1.49 1.27 1.74 7.02×10
-07
 1.30 1.11 1.52 0.0012 427 413 1041 1307 413 0.19 
rs710521[AA,AG] x rs8102137[CC,CT] x 
GSTM1 null 1.47 1.26 1.72 1.19×10
-06
 1.36 1.17 1.59 7.91×10
-05
 475 447 993 1273 447 0.11 
rs710521[AA,AG] x rs11892031[AA,AC] 1.41 1.23 1.63 1.68×10
-06
 1.31 1.14 1.51 0.0001 801 821 667 899 667 0.10 
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x GSTM1 null 
rs9642880[GT,TT] x rs11892031[AA] x 
GSTM1 null 1.42 1.23 1.65 2.21×10
-06
 1.37 1.19 1.59 2.15×10
-05
 571 545 897 1175 545 0.05 
rs9642880[GG,GT] x 
rs11892031[AA,AC] x GSTM1 present 0.70 0.60 0.81 2.38×10
-06
 0.69 0.60 0.80 1.02×10
-06
 441 659 1027 1061 441 0.01 
rs9642880[GT,TT] x rs710521[AA,AG] x 
GSTM1 null 1.42 1.22 1.64 3.23×10
-06
 1.37 1.18 1.58 1.85×10
-05
 627 607 841 1113 607 0.05 
rs9642880[GG,GT] x rs1495741[AA,AG] 
x GSTM1 present 0.70 0.61 0.82 3.42×10
-06
 0.70 0.60 0.82 3.60×10
-06
 423 629 1045 1091 423 0.00 
rs8102137[CC,CT] x rs11892031[AA,AC] 
x GSTM1 null 1.43 1.23 1.66 4.20×10
-06
 1.31 1.13 1.52 0.0004 500 486 968 1234 486 0.11 
"Reference" is the group of all genotypes except for the considered variant combination (i.e., the complement of the variant combination). E.g. the 
reference group for variant combination "rs11892031 [AA] x GSTM1 null" is "rs11892031 [AC, CC] and or GSTM1 present".  
Min. freq.: Lowest frequency of the risk combination and the reference genotypes, respectively, observed in cases and controls 
OR diff.: Difference between the published OR (Schwender et al. 2012) and the OR in the NBCS 
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Table 3. Different variant combinations are relevant in smokers and never smokers. The best (lowest P value, minimum frequency 100) single 
polymorphisms and the best two- to four-variant combinations discovered in the combined IfADo and Nijmegen Bladder Cancer Studies, unadjusted 
odds ratios (OR), 95% confidence intervals (CIs) and P values are shown (A). Furthermore the unadjusted OR of the reference group (complement of 
the variant combination) compared to the variant combination is given (1/OR). Both, OR and 1/OR, are highlighted grey and are printed bold in case of 
exceeding 1 significantly. The best combinations found in current and never smokers could be replicated in the New England and Spanish Bladder 
Cancer Studies (B) using rs10775480 and rs10853535 as proxies for rs1058396 and rs17674580 (r²=0.75 and r²=0.66) [19]. Results for the IfADo and 
Nijmegen study groups as well as age, gender, smoking habits and study group adjusted OR, 95% CIs and P values of the Wald test are given in 
Supplementary Table 5. Performance of the best combinations in the other subgroups is shown in Supplementary Table 10.  
 
C. Best combinations in the Discovery series (combined IfADo case-control series and Nijmegen Bladder Cancer Study) 
 Number of 
variants 
 
Cases Controls 
  
95% CI 
 
Subgroup Variant combinations N % N % OR 1/OR Lower Upper P value 
All 1 GSTM1 present 1252 0.42 1622 0.49 0.75 1.34 0.68 0.83 1.16×10
-08
 
2969 cases 2 GSTM1 present × rs9642880[GG,GT]  913 0.31 1283 0.39 0.69 1.44 0.62 0.77 6.95×10
-12
 
3285 controls 3 GSTM1 present × rs9642880[GG,GT] ×  
rs17674580[CC,CT] 
767 0.26 1129 0.34 0.67 1.50 0.60 0.74 2.59×10
-13
 
  4 GSTM1 present × rs9642880[GG,GT] ×  
rs17674580[CC,CT] × rs2294008[CC,CT] 
586 0.20 920 0.28 0.63 1.58 0.56 0.71 2.83×10
-14
 
Ever 1 GSTM1 present 876 0.42 1038 0.49 0.78 1.29 0.69 0.88 4.70×10
-05
 
2069 cases 2 GSTM1 present × rs9642880[GG,GT] 640 0.31 835 0.39 0.70 1.43 0.61 0.79 3.15×10
-08
 
2136 controls 3 GSTM1 present × rs9642880[GG,GT] ×  
rs2294008[CC,CT] 
490 0.24 684 0.32 0.66 1.52 0.57 0.75 1.86×10
-09
 
  4 GSTM1 present × rs9642880[GG,GT] × 
rs2294008[CC,CT] × rs798766[CC,CT] 
464 0.22 660 0.31 0.65 1.55 0.56 0.74 6.17×10
-10
 
Current 1 GSTM1 null 402 0.59 349 0.53 1.30 0.77 1.05 1.62 1.66×10
-02
 
676 cases 2 GSTM1 present × rs710521[AG,GG] 108 0.16 153 0.23 0.63 1.59 0.48 0.83 9.03×10
-04
 
659 controls 3 GSTM1 null × rs11892031[AA] ×  
rs1058396[AG,GG] 
303 0.45 226 0.34 1.56 0.64 1.25 1.94 8.75×10
-05
 
  4 GSTM1 null × rs11892031[AA] × 
rs1058396[AG,GG] × rs1014971[AA,AG] 
272 0.40 194 0.29 1.61 0.62 1.29 2.03 3.70×10
-05
 
Former 1 rs9642880[TT] 394 0.28 303 0.21 1.53 0.65 1.29 1.81 1.33×10
-06
 
1393 cases 2 rs9642880[GG,GT] × rs17674580[CC,CT] 831 0.60 1029 0.70 0.64 1.55 0.55 0.75 2.15×10
-08
 
1477 controls 3 rs9642880[TT] × rs8102137[CC, CT] × 
rs1495741[AA,AG] 
229 0.16 135 0.09 1.96 0.51 1.56 2.45 6.67×10
-09
 
  4 rs9642880[TT] × rs8102137[CC,CT] × 
rs1495741[AA,AG] × rs17674580[CC,CT] 
204 0.15 110 0.07 2.13 0.47 1.67 2.72 1.29×10
-09
 
Never 1 rs1014971[AA] 207 0.51 452 0.41 1.53 0.66 1.22 1.92 2.88×10
-04
 
406 cases 2 rs1014971[AA] × rs17674580[CT,TT] 142 0.35 252 0.23 1.84 0.54 1.44 2.36 1.33×10
-06
 
1115 controls 3 rs1014971[AA] × rs11892031[AA] ×  161 0.40 276 0.25 2.00 0.50 1.57 2.54 1.81×10
-08
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rs1058396[AG,GG] 
 4 rs1014971[AA] × rs11892031[AA] ×  
rs1058396[AG,GG] × rs8102137[CC,CT] 
100 0.25 125 0.11 2.59 0.39 1.93 3.47 1.87×10
-10
 
 
D. Replication series: New England and Spanish Bladder Cancer Studies 
 
Number of 
variants 
 
Cases Controls   95% CI  
Subgroup Variant combinations N % N % OR 1/OR Lower Upper P value 
All 1 GSTM1 present 823 0.40 1033 0.48 0.70 1.42 0.62 0.79 2.56×10
-08
 
2080 cases 2 GSTM1 present × rs9642880[GG,GT]  598 0.29 793 0.37 0.70 1.43 0.62 0.80 7.89×10
-08
 
2167 control 3 GSTM1 present × rs9642880[GG,GT] ×  
rs17674580[CC,CT]
1 
482 0.23 646 0.30 0.71 1.41 0.62 0.82 1.42×10
-06
 
  4 GSTM1 present × rs9642880[GG,GT] ×  
rs17674580[CC,CT]
1
 × rs2294008[CC,CT] 
383 0.18 517 0.24 0.72 1.39 0.62 0.84 1.88×10
-05
 
Ever 1 GSTM1 present 642 0.39 606 0.46 0.76 1.32 0.65 0.88 1.79×10-
04
 
1654 cases 2 GSTM1 present × rs9642880[GG,GT] 506 0.31 502 0.38 0.72 1.39 0.62 0.84 2.98×10
-05
 
1325 control 3 GSTM1 present × rs9642880[GG,GT] ×  
rs2294008[CC,CT] 
397 0.24 401 0.30 0.73 1.37 0.62 0.86 1.29×10
-04
 
  4 GSTM1 present × rs9642880[GG,GT] × 
rs2294008[CC,CT] × rs798766[CC,CT] 
385 0.23 391 0.30 0.73 1.37 0.62 0.85 1.21×10
-04
 
Current 1 GSTM1 null 458 0.59 238 0.56 1.17 0.85 0.92 1.49 0.20 
776 cases 2 GSTM1 present × rs710521[AG,GG] 115 0.15 86 0.20 0.70 1.43 0.51 0.95 0.02 
428 controls 3 GSTM1 null × rs11892031[AA] ×  
rs1058396[AG,GG]
2 
290 0.37 118 0.28 1.58 0.63 1.22 2.05 4.96×10
-04
 
  4 GSTM1 null × rs11892031[AA] × 
rs1058396[AG,GG]
2
 × rs1014971[AA,AG] 
270 0.35 114 0.27 1.49 0.67 1.14 1.93 3.03×10
-03
 
Former 1 rs9642880[TT] 198 0.22 188 0.20 1.09 0.92 0.87 1.36 0.47 
920 cases 2 rs9642880[GG,GT] × rs17674580[CC,CT]
1 
580 0.63 605 0.65 0.93 1.08 0.76 1.12 0.42 
932 controls 3 rs9642880[TT] × rs8102137[CC, CT] × 
rs1495741[AA,AG] 
113 0.12 94 0.10 1.25 0.80 0.94 1.67 0.13 
  4 rs9642880[TT] × rs8102137[CC,CT] × 
rs1495741[AA,AG] × rs17674580[CC,CT]
1 
80 0.09 74 0.08 1.11 0.90 0.80 1.54 0.55 
Never 1 rs1014971[AA] 155 0.51 303 0.44 1.32 0.76 1.01 1.72 0.048 
305 cases 2 rs1014971[AA] × rs17674580[CT,TT]
1 
110 0.36 213 0.31 1.26 0.79 0.95 1.67 0.11 
688 controls 3 rs1014971[AA] × rs11892031[AA] ×  
rs1058396[AG,GG]
2 
93 0.30 176 0.26 1.27 0.79 0.94 1.71 0.11 
 4 rs1014971[AA] × rs11892031[AA] ×  
rs1058396[AG,GG]
2
 × rs8102137[CC,CT] 
54 0.18 81 0.12 1.60 0.63 1.10 2.33 0.013 
1
 rs10853535 was used as a proxy for rs17674580 
2
 rs10775480 was used as a proxy for rs1058396 
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Table 4. Variants in the ten best four-variant combinations differ between smokers and never smokers. Subgroups are compared regarding the 
occurrence of each variant in the ten best combinations by chi-squared or fishers exact tests. Unadjusted P values, ORs and 95% CIs of all ten best 
single variants, two-, three and four-variant combinations are given in Supplementary Table 8A-E. Tests for the ten best two- and three-variant 
combinations are given in Supplementary Table 9A, B. P values P ≤ 0.05 are printed bold. 
Variants Nearest gene All 
Ever 
smokers 
Current 
smokers 
Former 
smokers 
Never 
smokers P value P C vs. F P C vs. N P F vs. N P E vs. N 
GSTM1 GSTM1 9 8 10 0 0 0.0005 1.08×10
-05
 1.08×10
-05
 1.0000 0.0007 
rs11892031[A/C] UGT1A 3 2 6 4 8 0.2569 0.2105 0.0031 1.08×10
-05
 1.08×10
-05
 
rs1495741[A/G] NAT2 1 1 2 6 3 0.2374 0.1698 1.0000 0.0573 0.0055 
rs1058396[A/G] SLC14A1 2 2 8 4 9 0.0770 0.6563 0.6285 0.1698 0.0230 
rs17674580[C/T] SLC14A1 4 3 0 5 2 0.0420 0.1698 1.0000 0.3698 0.5820 
rs2294008[C/T] PSCA 6 8 0 1 1 1.0000 0.0325 0.4737 0.3498 1.0000 
rs2978974[A/G] PSCA 1 1 2 0 0 0.3198 1.0000 1.0000 1.0000 0.0055 
rs1014971[A/G] CBX6-APOBEC3A 0 0 3 0 10 0.0005 0.4737 0.4737 1.0000 1.0000 
rs710521[A/G] TP63 2 1 1 2 1 1.0000 1.0000 1.0000 1.0000 1.0000 
rs798766[C/T] TACC3 2 2 1 0 2 0.7266 1.0000 1.0000 0.4737 1.0000 
rs8102137[C/T] CCNE1 0 2 5 8 4 0.2689 0.3498 1.0000 0.1698 0.6285 
rs9642880[G/T] MYC 10 10 2 10 0 0.0005 0.0007 0.4737 1.08×10
-05
 1.08×10
-05
 
P value: P value of the exact chi-squared test of homogeneity of the variant frequency in the ten best four-variant combinations in current, former and never smokers 
The P value of Fisher's exact test of homogeneity of the variant frequency in the ten best four-variant combinations is given for current vs. former smokers (P C vs. 
F), current vs. never smokers (P C vs. N), former vs. never smokers (P F vs. N), and ever vs. never smokers (P E vs. N).  
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Figure 1. 
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Figure 2. 
